Image Ben Hargreaves Oncology Beyond COVID-19: mRNA vaccines aim to revolutionise cancer c... mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. Market Access Inflation Reduction Act proves positive boost for biosimilar... For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments. R&D Weight loss gold rush: Developers vie for next blockbuster t... Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies. Patients The high cost of inequality: High US healthcare spend falls ... Healthcare in the US is facing a cost crisis and one part of the puzzle could be to address the inequality that persists within the system. Load more results
Oncology Beyond COVID-19: mRNA vaccines aim to revolutionise cancer c... mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment.
Market Access Inflation Reduction Act proves positive boost for biosimilar... For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments.
R&D Weight loss gold rush: Developers vie for next blockbuster t... Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.
Patients The high cost of inequality: High US healthcare spend falls ... Healthcare in the US is facing a cost crisis and one part of the puzzle could be to address the inequality that persists within the system.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
